FARMINGDALE, N.Y., Nov. 12 Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year, exclusive distribution agreement with Dalpharma, Ltd., based in Riyadh, Saudi Arabia, for the distribution of the SonicOne® Ultrasonic Wound Debrider. The agreement provides Dalpharma with the rights to sell in Saudi Arabia, Yemen, Oman, and Egypt, and includes minimum purchase requirements.
Advertisement
Dalpharma is recognized in several Middle Eastern countries as a service oriented distributor of state-of-the-art medical devices and capital equipment, with special emphasis on the wound care market segment.
Advertisement
The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.
"Misonix welcomes Dalpharma to our expanding family of distributors and represents one of our early partnerships in the important Saudi Arabian and Middle East market places," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Dalpharma's reputation as a high integrity, customer focused sales organization is well known to Misonix."
About Misonix:
Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Investor Relations Contact: Cameron Associates, Inc. 212-245-4577 [email protected]
SOURCE Misonix, Inc.
